Prostate Cancer Therapy
Study findings from University Medical Center, Department of Nuclear Medicine provide new insights into prostate cancer therapy
Published in Drug Law Weekly, August 25th, 2009
Fresh data on prostate cancer are presented in the report '(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.' "(188)Re-HEDP is indicated for the treatment of pain in patients with painful osteoblastic bone metastases, including hormone-refractory prostate cancer patients. Efficacy may be improved by adding chemotherapy to the treatment regimen as a radiation sensitizer," investigators in Utrecht, Netherlands report.
"The combination of (188)Re-HEDP and capecitabine (Xeloda®) was tested in a clinical phase I study. Patients with hormone-refractory prostate cancer were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-08-25)
More Articles from Drug Law Weekly
- Astellas Pharma US, Inc.
Update on Astellas' Request for Rigorous Testing and Safety-Related Labeling for Anti-Rejection Medications - Breast Cancer
Recent studies from University of California, Medical Department add new data to psychiatry - Bureau of Alcohol, Tobacco, Firearms and Explosives
ATF, U.S. Attorney, Arizona Attorney General and Firearms Industry Join Forces to Stop Illegal Purchases of Firearms in Tucson - Defibrillators
Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches - Generics
Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) - HIV/AIDS
Federal Judge Sentences Defendants Who Perpetrated $10.9 Million Medicare Fraud HIV Infusion Scheme - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
